Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation. It sells its products through third-party distributors. It has a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. to focus on global development and commercialization of next-generation IRE technologies. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.…
Baird Medical Enters South Korea Market through Strategic Distribution Partnership with ALLIS MED
Baird Medical Investment Holdings (NASDAQ: BDMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 146 employees.
The shares were at 0.0897 USD on 20 November 2026, down 93.0% over 52 weeks. Its 52-week range is 0.0725 USD to 3.700 USD: the price is 97.6% below the high and 23.7% above the low.
Its market capitalisation is 5.07M USD.
Baird Medical Investment Holdings reports return on equity of -87.0%, an operating margin of -58.5% and revenue up 24.6% year over year.
Its debt exceeds its cash by 18.48M USD, a debt-to-equity ratio of 0.62. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.